ANKTIVA
nogapendekin alfa inbakicept · nogapendekin alfa inbakicept-pmln · N-803 · NAI · ALT-803 Protein Target: IL-15 receptor, IL-15
ImmunityBio
Most recent annual filing: 2026-02-23
- ANKTIVA NMIBC filing2026ANKTIVA NMIBC filing, 2026, material
- QUILT-2.005 sBLA filing2026QUILT-2.005 sBLA filing, 2026, routine
- Papillary-only sBLA PDUFA dateJan 6, 2027Papillary-only sBLA PDUFA date, Jan 6, 2027, routine
- SRS/Altor CVR arbitration corporate updateJan 25, 2027SRS/Altor CVR arbitration corporate update, Jan 25, 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (16 active programs)
ANKTIVA
nogapendekin alfa inbakicept · nogapendekin alfa inbakicept-pmln · N-803 · NAI Protein Target: IL-15 receptor, IL-15, IL-15R
ANKTIVA
nogapendekin alfa inbakicept · N-803 Protein Target: IL-15 receptor, IL-15
PD-L1 t-haNK
CD19 t-haNK
M-ceNK
- Undisclosed indication
recombinant BCG
rBCGAd-HPV
hAd5 TAA E6/E7 Gene Therapy Target: HPV E6, HPV E7
- HPV-Associated Cancers
hAd5 PSA
Gene Therapy Target: PSA
hAd5 TriAd
Gene Therapy Target: CEA, MUC1, Brachyury
3M-052
Small Molecule Target: TLR7, TLR8
- Undisclosed indication
Technology platforms
Cancer BioShield
First-in-class immunotherapy platform designed to restore immune competence by reversing lymphopenia; comprises cytokine fusion proteins (IL-15 superagonist ANKTIVA), adenovirus-vectored vaccines (hAd5), allogeneic and autologous NK-cell therapies (CAR-NK, M-ceNK), and additional immunomodulators; focus areas: oncology (bladder, lung, pancreatic, GBM, NHL) and infectious diseases
Targets: IL-15 receptor, PD-L1, CD19, IL-15, NK cells, CD8+ T cells, cytotoxic T cells, memory T cells, IL-15R
Biotech Distilled coverage (18)
- 2026-08-05 UPDATE: ImmunityBio (IBRX) - The Eighth Straight Beat, and the GAAP Number That Scared Everyone Off 🔒 Paid
- 2026-07-30 UPDATE: ImmunityBio (IBRX) - The UAE Approves the Label the FDA Hasn’t 🔒 Paid
- 2026-05-20 UPDATE: ImmunityBio (IBRX) - The Papillary Loop Officially Closes
- 2026-05-19 UPDATE: ImmunityBio (IBRX) - AUA 2026 Lands the Competitive Receipts on Nadofaragene and TAR-200 🔒 Paid
- 2026-05-19 UPDATE: ImmunityBio (IBRX) - The BCG Shortage Bear Case Just Got a Second Supplier and a Patent Fence 🔒 Paid
- 2026-05-08 UPDATE: ImmunityBio (IBRX) - The 10-Q Buries Three New Lawsuits and a Washington AG Investigation 🔒 Paid
- 2026-04-27 UPDATE: ImmunityBio (IBRX) - The Dilution Gap Closes, But the Founder’s Mouth Opens a New One 🔒 Paid
- 2026-03-29 UPDATE: ImmunityBio (IBRX) - Locks the First-Line Data Deck. Enrollment Risk Eliminated.
- 2026-03-21 UPDATE: ImmunityBio (IMRX) - Unlocking the NCCN Cheat Code and Entering Asia 🔒 Paid
- 2026-03-14 UPDATE: ImmunityBio (IBRX) Closes the Papillary Loop and Flexes its Manufacturing Muscle 🔒 Paid
- 2026-02-28 UPDATE: ImmunityBio (IBRX) Secures the First-Line Front. The Fundamentals Catch Up to the Hype. 🔒 Paid
- 2026-02-21 Update: ImmunityBio (IBRX) Goes Global. The Dilution Gap Meets the Commercial Avalanche. 🔒 Paid
- 2026-01-24 Update: ImmunityBio (IBRX) Throws the Kitchen Sink at Glioblastoma. Did it Just Break the Curse?
- 2026-01-22 Update: ImmunityBio (IBRX) Might Have Just Dodged a Regulatory Bullet. The Papillary Problem Getting Resolved?
- 2026-01-18 Update: ImmunityBio (IBRX) Delivers a Trifecta of News. The Valley of Death is Filling Up with Revenue.
- 2026-01-14 UPDATE : ImmunityBio (IBRX) Secures World-First Lung Cancer Approval in Saudi Arabia. The Sandbox Strategy is Live.
- 2026-01-13 Update: Is ImmunityBio (IBRX) Playing the Saudi Card? Is the Funding Gap About to Close? 🔒 Paid
- 2026-01-11 Immunitybio (IBRX): Scientific Deep Dive for ANKTIVA and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.